35%
Longer
Lifespan
Inspired by
Human Health.
Developed for People. Reformulated for Pets.
OKAVA reconfigures FDA-approved products, originally designed to treat humans, for use in dogs and cats, so that they can receive the same quality care.
A Paradigm Shift
Traditional drug development is notoriously expensive, time-consuming, and risky.
OKAVA breaks this cycle by leveraging human R&D investments and repurposing
human innovations for dogs and cats. We call it the “People-to-Pet Pipeline.
Advantages
Leverage decades
and billions spent on
human R&D
Although every human medicine undergoes animal testing as part of the FDA-approval process, it generally takes decades for medical advancements to trickle down to the veterinary setting. OKAVA leverages those investments and redirects that capital to quickly advance veterinary medicine.
Learn from the human
clinical experience
Human medicine is our crystal ball. Years of clinical experience in human patients guides our pet health "Humanization” endeavors. We know what the future of pet health looks like because its already here for humans.
Capital efficient,
high ROI model
Each product are developed for $5M to $7M. This low, 1-time investment, coupled with attractive profit margins, yields high financial returns.
Largely eliminate
technical &
regulatory risk
By starting with [human] approved products that are already safely and effectively used in pets, we avoid the pitfalls associated with traditional drug development.
Quickly develop
products
Repurposing allows us to streamline product development. Unique and meaningful pet-specific products can be developed and launched in under 5 years.
